Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OSI-906 (Linsitinib (OSI-906)) is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 33.00 | |
5 mg | In stock | $ 52.00 | |
10 mg | In stock | $ 74.00 | |
25 mg | In stock | $ 118.00 | |
50 mg | In stock | $ 168.00 | |
100 mg | In stock | $ 233.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 58.00 |
Description | OSI-906 (Linsitinib (OSI-906)) is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Linsitinib selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGF-1R stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis. |
Targets&IC50 | IGF-1R:35 nM, Insulin receptor:75 nM, IRR:75 nM |
In vitro | OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50?of 0.021 to 0.810 μM. [1] |
In vivo | OSI-906 effectively inhibits tumor growth in IGF-1R-driven xenograft mouse models, achieving 100% tumor growth inhibition (TGI) and 55% regression at a 75 mg/kg dosage, and 60% TGI with no regression at 25 mg/kg. Its elimination half-life varies across species, recorded at 1.18 hours in dogs, 2.64 hours in rats, and 2.14 hours in mice. Additionally, the Vmax of OSI-906 is not dose-proportional when administered in varying single doses to female Sprague-Dawley rats and CD-1 mice. At 25 mg/kg, OSI-906 raises blood glucose levels after 12 days of treatment. A single 75 mg/kg dose in an IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model maximizes IGF-1R phosphorylation inhibition (80%) between 4 and 24 hours, correlating with plasma drug concentrations of 26.6-4.77 μM. Furthermore, a 60 mg/kg dose in NCI-H292 xenograft mice diminishes glucose uptake at 2, 4, and 24 hours post-treatment, indicating OSI-906's potent antitumor efficacy in NCI-H292 xenograft mouse models. |
Kinase Assay | Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R,IR,EGFR and KDR) or at Upstate Inc.by a radiometric method with ATP at 100 μM concentration.In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase.The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm.All assays use purified recombinant kinase catalytic domains.Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house.IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration.A minimum of three measurements,performed in duplicate,are carried out with in-house assays unless otherwise indicated.OSI-906 at a concentration of 1 μM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit. |
Cell Research | For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.(Only for Reference) |
Synonyms | OSI-906 |
Molecular Weight | 421.49 |
Formula | C26H23N5O |
CAS No. | 867160-71-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 78 mg/mL (185.1 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Linsitinib 867160-71-2 Tyrosine Kinase/Adaptors IGF-1R OSI 906 Inhibitor inhibit OSI-906 Insulin Receptor OSI906 inhibitor